BBA
RPRX

Baker Bros. Advisors’s Repros Therapeutics Inc. RPRX Stock Holding History

Baker Bros. Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,955,944
Closed -$14.5M – 140
2015
Q3 		$14.5M Hold
1,955,944
– – 0.13% 52
2015
Q2 		$14M Sell
1,955,944
-44,056
-2% -$343K 0.12% 55
2015
Q1 		$17.2M Hold
2,000,000
– – 0.14% 46
2014
Q4 		$19.9M Sell
2,000,000
-778,654
-28% -$6.64M 0.2% 38
2014
Q3 		$27.5M Hold
2,778,654
– – 0.35% 28
2014
Q2 		$48.1M Hold
2,778,654
– – 0.59% 23
2014
Q1 		$49.3M Hold
2,778,654
– – 0.63% 24
2013
Q4 		$50.8M Hold
2,778,654
– – 0.72% 22
2013
Q3 		$74.5M Hold
2,778,654
– – 1.06% 15
2013
Q2 		$51.3M Buy
+2,778,654
New +$49.1M 1.01% 16

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Baker Bros. Advisors's RPRX Position: Q4 2015 in Review

Baker Bros. Advisors sold out of Repros Therapeutics Inc. (RPRX) in Q4 2015, closing a stake of 1,955,944 shares — an estimated $14.5M sold.

Baker Bros. Advisors first reported a position in RPRX in Q2 2013 and held it in 10 quarters. The position peaked at $74.5M in Q3 2013. 56 funds tracked by Wall St. Rank hold RPRX as of Q4 2015.

  • Baker Bros. Advisors reported no remaining Repros Therapeutics Inc. position as of Q4 2015 after selling out during the quarter.
  • Baker Bros. Advisors sold 1,955,944 Repros Therapeutics Inc. shares in Q4 2015, an estimated $14.5M.
  • Baker Bros. Advisors first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 10 quarters.
  • Baker Bros. Advisors's Repros Therapeutics Inc. position peaked at $74.5M in Q3 2013.
  • 56 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2015.

Based on Baker Bros. Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.